Intuniv

Guanfacine, the active ingredient in Intuniv, is an alpha‑2 adrenergic agonist presented as an extended‑release tablet for oral use. It belongs to the central antihypertensive class and works by reducing sympathetic outflow from the central nervous system, thereby treating attention deficit hyperactivity disorder in children and adolescents and is also employed off‑label for hypertension.

GNH USA supplies Intuniv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Intuniv (guanfacine) is an alpha‑2A adrenergic receptor agonist used primarily in the management of neurodevelopmental and cardiovascular conditions.

- Attention deficit hyperactivity disorder (ADHD): improves attention, reduces hyperactivity and impulsivity in children and adolescents. - Hypertension (off‑label): lowers blood pressure by decreasing sympathetic nervous system activity. - Tourette syndrome (off‑label): may reduce the frequency and severity of motor and vocal tics.

Intuniv may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Drowsiness - Fatigue - Headache - Dry mouth

Serious or Rare Side Effects: - Bradycardia - Severe hypotension - Syncope

Before initiating therapy with Intuniv, consider the following precautions: - Monitor blood pressure and heart rate: assess baseline values and follow up regularly. - Adjust dose gradually: titrate to the lowest effective dose to minimize adverse effects. - Use caution in patients with cardiac disease: evaluate for conduction abnormalities. - Avoid abrupt discontinuation: taper the dose to prevent rebound hypertension. - Use with caution in hepatic impairment: dose may need adjustment. - Store at ambient temperature: keep in the original pack, protect from moisture.

Intuniv can interact with several medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid):\n- CYP3A4 inhibitors: may increase guanfacine plasma concentrations. - CYP3A4 inducers: may reduce guanfacine effectiveness. - Clonidine: additive hypotensive effects.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of dizziness.